Related Experiment Video
Updated: Aug 10, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Delayed-release verapamil hydrochloride in chronic atrial fibrillation. Reducing the heart rate]
1Medizinische Klinik, Abteilung Kardiologie, Universität Göttingen.
Abstract:
In an open clinical trial, the therapeutic effect of sustained-release verapamil hydrochloride was investigated in 40 patients with chronic atrial fibrillation. As required, the daily dose was increased from 240 mg to 480 mg. A clinically relevant, statistically significant decrease in the heart rate was observed in almost all the patients. Since only four patients experienced mild side effects, with no major clinical significance, the preparation has a positive benefit/risk ratio for the indication investigated.
Related Concept Videos
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...

